Jun 28 |
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Jun 20 |
Institutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$25m market cap decline as longer-term profits stay in the green
|
Jun 10 |
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
|
Jun 10 |
Pyxis Oncology: Promising Research Amid Cash Constraints
|
May 30 |
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
|
May 14 |
Pyxis Oncology GAAP EPS of -$0.06, revenue of $16.1M
|
May 14 |
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
|
May 9 |
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
|
Mar 28 |
Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait
|
Mar 27 |
Pyxis Oncology files to sell 10.46M common shares for holders
|